Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer von Joseph, N., Dovedi, S.J., Thompson, C., Lyons, J., Kennedy, J., Elliott, T., West, C.M., Choudhury, A.

Volltext

SP-0016: Radiotherapy and immunotherapy combination: paradigm changing or just hype? von Dovedi, S.J.

Volltext

76P Immune engager compounds screening using CRC patient-derived organoids von Pinna, C.M.A., Rakhimova, K., Zhang, J., Tee, L., Bills, L., Millar, D., Blanc, C., Lal, N., Rottoli, E., Oisin, H., Gaspar, M., Lara, R., Cemerski, S., Dovedi, S.J., Beggs, A.D.

Volltext

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery von Mosely, S.I.S, Prime, J.E, Sainson, R.C.A, Koopmann, J.-O, Wang, D.Y.Q, Greenawalt, D.M, Ahdesmaki, M.J, Leyland, R, Mullins, S, Pacelli, L, Marcus, D, Anderton, J, Watkins, A, Ulrichsen, J.C, Brohawn, P, Higgs, B.W, McCourt, M, Jones, H, Harper, J.A, Morrow, M, Valge-Archer, V, Stewart, R, Dovedi, S.J, Wilkinson, R.W

Volltext bestellen